Background {#Sec1}
==========

Juvenile idiopathic arthritis (JIA) is a longstanding inflammatory arthritis of unknown origin in a child below 16 years of age. In the Nordic European countries is found an incidence of 15 per 100,000 children per year \[[@CR1]\]. JIA includes several clinical subtypes, probably of different pathogenesis. The outcome in terms of functional ability has changed greatly during the last two decades due to progress in medical anti-inflammatory treatment; only few patients nowadays become functionally impaired during childhood or as young adults. However, a cure for JIA has not been found, and less than half of the patients achieve full and permanent remission \[[@CR2]--[@CR4]\].

Premature development of atherosclerosis is a well described feature of several chronic inflammatory diseases, including rheumatoid arthritis (RA) \[[@CR5]--[@CR7]\]. The clinical similarity between RA and JIA has given rise to several studies of the vasculature of patients with JIA, leaving no doubt that also JIA is associated with early signs of subclinical atherosclerosis \[[@CR8], [@CR9]\]. Persisting systemic inflammation may be a primary contributor, but other known risk factors for development of atherosclerosis, such as dyslipidemia, obesity, and sedentary behavior may contribute as well, and should be addressed prophylactically along with anti-inflammatory treatment.

In the general population, a high level of total cholesterol (TC), with a high fraction of low-density lipoprotein cholesterol (LDLc) and a low fraction of high-density lipoprotein cholesterol (HDLc), is associated with development of atherosclerosis \[[@CR10]\]. Observational studies show that patients with RA have a nearly 50 % increased risk of experiencing clinically significant cardiovascular events compared to the general population \[[@CR6], [@CR7]\], but have a cholesterol profile different from the atherogenic profile described above. It is generally accepted that untreated RA, with the highest risk of clinically important atherosclerosis, is associated with low levels of HDLc and LDLc \[[@CR10]--[@CR12]\]. This is intriguing, as lipid deposits in the arterial intima are the hallmark of atherosclerosis.

Most previous studies of cholesterol fractions in JIA reported decreased levels of HDLc, while the level of LDLc varies between studies; a consistent pattern in regard to concomitant clinical or biochemical markers of inflammation is not evident in the literature \[[@CR13]--[@CR19]\].

Overweight and obesity in children and adolescents is typically associated with increased TC and decreased HDLc \[[@CR20], [@CR21]\]. The worldwide rise in the incidence of overweight and obesity reported in children and adolescents could also occur among patients with JIA and may also contribute to changes in cholesterol fractions seen in children with JIA \[[@CR19]\].

A low level of physical activity (PA) may *per se* be associated with a raised level of TC \[[@CR22]\]. A low level of PA in patients with JIA, as found in a recent study of PA in children with JIA \[[@CR23]\], may possibly contribute to the divergent findings regarding lipid fractions in JIA.

The purpose of this study is to examine the levels in the blood of the cholesterol fractions (TC, LDLc, and HDLc), in children and adolescents with JIA, testing the hypothesis that the cholesterol fractions are correlated with inflammation as well as with overweight and PA.

Methods {#Sec2}
=======

Design {#Sec3}
------

This is a descriptive cross-sectional study of blood cholesterol fractions, disease characteristics, anthropometrics, and objectively measured PA in patients with JIA. The patient population and level of PA was recently described in detail \[[@CR23]\].

Patients {#Sec4}
--------

All patients with JIA, 7 to 20 years of age, followed during a period from May 2011 to May 2013 at a population based out-patient specialized center for pediatric rheumatology covering Copenhagen and the eastern part of Denmark, were invited to participate. No one had significant chronic conditions other than JIA, especially no known conditions connected with dyslipidemia, and no patients received corticosteroid at the time of investigation, or had had recent intra-articular injection of corticosteroids. The patients were asked about family history of cardiovascular disease.

The patients were diagnostically sub-grouped in accordance with ILAR criteria \[[@CR24]\].

Of 260 eligible patients, 50 declined to participate for logistical or social reasons not related to their disease. Forty-four patients declined accelerometer monitoring but accepted clinical evaluation and blood tests. Thus a total of 210 patients were available for clinical evaluation and analyses of inflammatory markers and cholesterol fractions in the blood; 166 accepted to participate in the whole investigation, including monitoring with accelerometer, which was done in the weeks after clinical assessment and blood tests. Of these, 133 patients returned accelerometer monitoring results of a sufficient quality for evaluation as defined below (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Included patients

Clinical valuation of disease activity {#Sec5}
--------------------------------------

All participants were assessed clinically by a pediatrician experienced in pediatric rheumatology and not involved in the investigation. The patients were seen as part of a routine control, no one was seen because of flare. Disease activity was described by a composite score, Juvenile Arthritis Disease Activity Score including evaluation of 27 joints (JADAS27) \[[@CR25], [@CR26]\]: *i)* number of joints with active inflammation: cervical spine, elbows, wrists, metacarpophalangeal joints 1--3, proximal interphalangeal joints 1--5, hips, knees, ankles, *ii)* global disease scoring by physician, *iii)* global disease scoring by patient or parent according to age, and *iv)* truncated erythrocyte sedimentation rate (tESR). JADAS27 is measured on a scale from 0--57.

Global disease activity was scored using a visual analog scale (VAS) from 0 (no sign of disease) to 10 (maximal burden of disease) by the physician and the patients/parents (according to age). Remission was assessed according to Wallace criteria \[[@CR27]\].

Markers of inflammation in blood {#Sec6}
--------------------------------

C-reactive protein (CRP) was measured (Roche/Hitachi cobas c-system, Mannheim, Germany) by turbidimetry after precipitation of agglutinated antibodies to CRP; the lower detection limit is 0.15 mg/l. Myelo-related-protein complex 8/14 (MRP8/14) was measured quantitatively in serum by use of a commercial ELISA kit (Bühlmann Laboratories AG, Schönenbuch, Switzerland) according to the manufacturer's instructions. The principle is a sandwich technique with a monoclonal antibody specific to the MRP8/14 heterodimeric and polymeric complexes. Detection limit is \< 0.4 mikrogram/ml. Analysis of MRP8/14 was done on serum of blood samples frozen immediately after separation and stored at −80°. ESR was used in the JADAS27 truncated (tESR) according to the formula given by Consolaro et al. \[[@CR25]\]: after converting ESR values of ≤ 20 mm/h to 0 and ESR ≥ 120 to 120, tESR was calculated as (ESR (mm/h) - 20)/10 leaving a score of tESR from 0 to 10.

Treatment {#Sec7}
---------

All the patients were either in treatment with methotrexate (MTX) and/or biological DMARDS: TNF-α-inhibitors, IL-6 receptor inhibitor (tocilizumab) or T-cell co-stimulation inhibitor (abatacept), or solely by regular intra-articular injections of corticosteroid.

Anthropometry {#Sec8}
-------------

Overweight and obesity was assessed by BMI and waist-to-height ratio (WtH ratio).

Weight was measured with light clothing to the nearest 0.1 kg and height without shoes to the nearest 0.1 cm. BMI was calculated as weight/squared height, and standard deviation score (BMI SDS) was calculated by comparison with Danish age and gender specific BMI values, transformed into normal distribution \[[@CR28]\]. Waist circumference was measured with a non-stretchable tape, after expiration in a normal breathing rhythm, midway between the lower rib margin and the iliac crest. Pubertal stage (Tanner stage), was assessed by the patients or parents according to pictograms.

Blood pressure {#Sec9}
--------------

Blood pressure was measured with a Dinamap paediatric monitor (model XL, Critikon, Inc, Tampa, FL, USA) with the patient in a sitting position. The last two measurements out of three at each arm were used for calculation a mean systolic and a mean diastolic blood pressure. As blood pressure increases with age and is correlated to gender and height, the measured blood pressures (systolic or diastolic) were classified as normal (\<90-percentile), pre-hypertensive (between 90 and 95 percentile) or hypertensive (\>95 percentile) according to calculated percentiles in corresponding subgroups in data from a large group of normal American children of different age, sex and height, weight, and race \[[@CR29]\].

Lipids {#Sec10}
------

TC, LDLc, and HDLc were measured in plasma using Roche modular by enzymatic colorimetry (Cobas c-system, Roche Diagnostics, Mannheim, Germany).

Blood lipids were measured in a non-fasting state, as in the Danish pediatric reference material \[[@CR30]\].

Accelerometry {#Sec11}
-------------

Volume and pattern of PA was assessed during seven days by an accelerometer, ActiGraph model GT1M (ActiGraph Inc., Pensacola, FL, USA) a small, portable device worn fastened around the waist with an elastic band. The device measures vertical acceleration of the body and the reliability in measuring PA has been documented \[[@CR31]\]. The device cannot be used during swimming or bathing. Reasons for not wearing the device and the time spent without it were noted, as was time spent on horseback riding and cycling, since these physical activities are not captured accurately by accelerometry \[[@CR32]\].

The raw data were converted, after correction for non-wear time, by the ActiGraph software to *i)* mean counts per minute (cpm), a measure of average PA during total time of measurement, and *ii)* minutes per day spent in high PA (more than 3000 cpm), a cut-point routinely used by others, and *iii)* sedentary time assessed as average number of periods per day of more than 10 min with an activity of more than zero but less than 100 cpm. Only data collected during a minimum of 10 h per day for three days were considered reliable in assessing PA \[[@CR22]\]. Periods of more than 10 min of zero count were considered as periods of "non-wear".

Primary endpoints {#Sec22}
-----------------

Disease activity (JADAS, CRP, MRP8/14), anthropometry (BMI, WtH ratio), and PA (cpm, sedentary time, high activity) correlated to TC, LDLc, and HDLc.

Secondary endpoints {#Sec23}
-------------------

Correlations between cholesterol fractions and subgroup of JIA, treatment, disease duration, hypertension, gender, or Tanner stage were considered of explorative value.

Statistical analyses {#Sec12}
--------------------

Summary statistics mean and standard deviation (SD), median and range, or numbers with percentages, were chosen as descriptive measures.

Associations were tested by T-test, Pearson bivariate correlation analyses, and analysis of variance (one-way ANOVA). As a significant correlation was found between MRP8/14 and WtH ratio and HDLc, we performed a multiple linear regression analysis. All variables were log~10~ transformed, because of a non-normal distribution. Spearman's rho is calculated in analyses of JADAS, which could not be transformed to a normal distribution.

Significance (*p*) is given as two-tailed and with α = 0.004 after Bonferroni correction since we performed 12 independent tests on our primary endpoints: disease activity (JADAS/CRP), MRP8/14, anthropometry (BMI, WtH ratio), and PA (cpm, sedentary time, high activity) correlated to TC, LDLc, HDLc. Secondary endpoints were not corrected for multiple testing, as they were regarded as explorative.

All analyses were done in SPSS19, IBM Corp. IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp. USA, or in Excel 2010, Microsoft Corp. Redmond WA, USA.

Results {#Sec13}
=======

Patients, disease activity, and cholesterol fractions {#Sec14}
-----------------------------------------------------

The 210 included patients are described by gender, age, Tanner stage, anthropometrics, JIA subgroup, treatment, and disease duration (Table [1](#Tab1){ref-type="table"}) and broadly similar to the features of the Nordic JIA cohort \[[@CR3]\]. Mean age was 14.4 years, 58 % being in full puberty. Most patients were in treatment with biological DMARDs (68 %), by far most frequently with TNF-α inhibitors. Four patients (1.9 %) were in complete remission off medication, the treatment being withdrawn within the last 6 months. Seven of our patients had a family history of cardiovascular disease; the level of HDLc in these patients did not differ from the rest.Table 1Descriptive characteristics of the patientsTotal number210Females/males149 (71 %)/61 (29 %)Age (years)Mean 14.4 (SD 3.40) Median 15.00 (Range 7--21)Height (m)Mean 1.60 (SD 0.15) Median 1.62 (Range 1.14--1.87)Weight (kg)Mean 52.8 (SD 15.9) Median 53.8 (Range 18.5--97.0)BMI SDS ^a^Mean 0.4 (SD 1.17) Median 0.50 (Range −3.2--3.6)Waist-to-height ratio (163 patients)Mean 0.44 (SD 0.04) Median 0.43 (Range 0.35--0.62)Tanner Stadium121 (57.6 %) in Tanner Stage 5JIA subgroup: - Systemic6 (2.9 %) - Persisting Oligoarticular65 (31 %) - Polyarticular, RF negative53 (25 %) - Polyarticular, RF positive8 (3.8 %) - Psoriasis associated21 (10.0 %) - Enthesitis associated56 (26.7 %) - Undifferentiated1 (0.5 %) - Anti-Nuclear Antibodies (ANA) positive32 (15.2 %) - HLA-B27 positive40 (19 %)Treatment - Methotrexate40 (19 %) - Biologics +/− Methotrexate:142 (68 %)either TNF-α inhibitors130or IL-6 receptor inhibitor4or T-cell co-stim inhibitor CTLA-4-Ig8 - Solely by intra-articular injections13 (6.2 %) - None10 (4.8 %) - No information4 (1.9 %)Disease duration ^b^ in yearsMean 6.1 (SD 3,7) Median 5.2 (Range 0.5--17.3)Complete remission off medication4 (1.9 %)Summary statistics: Number with percentage in brackets, mean with SD in brackets, and median with range in brackets^a^ *BMI SDS* Body mass Index Standard Deviation Score, gender and age adjusted^b^Disease duration = duration of symptoms

The group of patients that refused participation (no. 50) was comparable with the 210 participating patients with regard to age, gender and subgroup of JIA. The group that participated only partly and the group that participated fully were comparable also in the distribution of BMI and actual disease activity (data not shown).

Data on clinical disease activity and markers of inflammation in the blood are presented in Table [2](#Tab2){ref-type="table"}. Numbers of inflamed joints, physician global VAS scores, ESR and CRP all indicate a general low level of disease activity in the patients.Table 2Markers of disease activityNumber of inflamed joints (0--27)Mean 1.17 (SD 2.26) Median 0.0 (Range 0--24)Physician global VAS (0--10)Mean 1.13 (SD 1.28) Median 1.00 (Range 0--6.5)Patient/parent global VAS (0--10)Mean 1.67 (SD 2.05) Median 0.8 (Range 0--10)ESR (mm/h)Mean 10.4 (SD 7.8) Median 9.0 (Range 1--58)Truncated ESR (tESR) (mm/h)Mean 0.08 (SD 0.40) Median 0.00 (Range 0--3,8)CRP (mg/l)Mean 1.98 (SD 3.64) Median 0.61 (Range 0.16--31.0)JADAS27 (0--57) ^a^Mean 4.2 (SD 4.1) Median 3.2 (Range 0--21)MRP8/14 (μg/ml)Mean 1.34 (SD 1.22) Median 1.03 (Range 0.18--13.75)Tendinitis and/or entesitis47 (22.4 %)Summary statistics: Number with percentage in brackets, mean with SD in brackets, and median with range in brackets^a^JADAS27 (0--57) (169 patients): a composite score of: number of joints with active disease (max 27), Physician global VAS, patient/parent global VAS and truncated ESR (tESR)

Mean values for TC, LDLc, and HDLc were all within the normal range for Danish Children \[[@CR30]\] (Table [3](#Tab3){ref-type="table"}).Table 3Cholesterol fractions and triglycerideDanish pediatric reference intervals \[[@CR30]\]Total cholesterol (TC) mmol/lMean 3.94 (SD 0.72)2.74--5.33High Density Lipoprotein fraction of cholesterol (HDLc) mmol/lMean 1.48 (SD 0.35)1.0--2.1Low Density Lipoprotein fraction of cholesterol (LDHc) mmol/lMean 2.16 (SD 0.58)1.1--3.6Summary statistics: Number with percentage in brackets, mean with SD in brackets

Correlation between primary and secondary outcomes and TC, HDLc, or LDLc {#Sec15}
------------------------------------------------------------------------

We found a significant negative correlation between HDLc and the inflammatory marker MRP8/14 with a Pearson correlation coefficient (r) of -- 0.343, (*p* \< 0.0005), while the correlation between HDLc and CRP and WtH ratio did not reach significance at the Bonferroni corrected level. HDLc and JADAS27 did not correlate significantly and we found no significant correlations between LDHc or TC and MRP8/14 or any other marker of inflammation. Neither TC nor cholesterol fractions correlated significantly with subgroups of JIA, treatment, duration of disease, gender, or Tanner stage. (Table [4](#Tab4){ref-type="table"}).Table 4Associations between cholesterol fractions and disease characteristics, fatness, and physical activity *P* values with correlation coefficients, and 95 % confidence interval in bracketsPatientsTC mmol/lHDLc mmol/lLDLc mmol/lGender T-test0.050.190.12Tanner stage (≤4 or = 5) T-test0.870.510.85Subgroup of JIA\
ANOVA0.050.850.09Treatment ^a^\
ANOVA0.830.680.98Disease duration\
Bivariate correlation0.930.190.84Primary endpoints:MRP 8/14\
Bivariate correlation, *p* value\
Pearson correlation coefficient, r\
95 % confidence interval0.20\<0.0005\*\
−0.343\
(−0.474 to −0.201)0.92CRP\
Bivariate correlation, *p* value\
Pearson correlation coefficient, r\
95 % confidence interval0.830.043\
−0.167\
(−0.319 to--0.015)0.63JADAS 27 ^b^\
Nonparametric correlation0.660.720.92Waist-to-height ratio\
Bivariate correlation, *p* value\
Pearson correlation coefficient r\
95 % confidence interval0.8240.018\
−0.187\
(−0.345 to--0.033)0.199BMI SDS\
Bivariate correlation0.150.130.49Counts per minute (cpm) (133 patients)\
Bivariate correlation0.230.250.33Sedentary time (minutes/day) (133 patients)\
Bivariate correlation0.230.610.11High activity (minutes/day) (133 patients)\
Bivariate correlation0.150.210.17*TC* total cholesterol, *HDLc* high density fraction of cholesterol, *LDLc* low density fraction of cholesterol\*Significance (*p*) is given as two-tailed and α selected after Bonferoni correction as 0.004 (12 independent tests)^a^Treatment: Methotrexate versus TNF-α inhibitor versus IL-6 receptor inhibitor versus T-cell co-stimulation inhibitor CTLA-4-Ig^b^JADAS27 (0--57): a composite score of: number of joints with active disease (max 27), Physician global VAS, patient/parent global VAS and truncated ESR (tESR)All parametric bivariate correlations have been performed after log10 transformation

Correlations between inflammatory markers {#Sec16}
-----------------------------------------

MRP8/14 correlated positively and significantly with CRP (*r* = 0.480, *p* \< 0.0005) and with JADAS27 (rho = 0.221, *p* = 0.006) (Table [5](#Tab5){ref-type="table"}). To our knowledge no studies provide normal values of MRP8/14 in children.Table 5Correlation between the inflammatory marker MRP8/14 and CRP (log10 transformed) and JADAS27MRP8/14 and CRP\
Pearson bivariate correlation*r* = 0.480 (95 % CI 0.347--0.598)*p* \< 0.0005MRP8/14 and JADAS27\
Nonparametric correlationrho = 0.221 (95 % CI 0.064--0.373)*p* = 0.006

Overweight and obesity and correlation to cholesterol and inflammation {#Sec17}
----------------------------------------------------------------------

Thirty percent of the patients had a BMI SDS above 1 SD, and 7.6 % had a BMI SDS above 2 SD compared to the Danish age and gender adjusted reference material \[[@CR28]\]. Only 5 patients had a BMI SDS below 2 SD.

Prehypertension defined as a diastolic or systolic blood-pressure between the 90. and 95. percentile, was seen in 17 % of the patients with an unsurprising association to BMI but with no correlation to MRP8/14.

Neither BMI nor WtH ratio showed a significant correlation to TC, HDLc, or LDLc (Table [4](#Tab4){ref-type="table"}). As a significant correlation was found between WtH ratio and MRP8/14 (Table [6](#Tab6){ref-type="table"}) we performed a multiple linear regression analysis of HDLc as dependent on the independent variables WtH ratio and MRP8/14. WtH ratio did not add significantly to the prediction of HDLc (β = −0.069, *p* = 0.395) while MRP8/14 remained significant (β = −0.330, *p* \< 0.0005) (Table [7](#Tab7){ref-type="table"}).Table 6Pearson correlation between inflammatory markers (MRP8/14 and CRP) and markers of fatness (waist-to-height ratio and BMI SDS)MRP8/14CRPWaist-to-height ratio (WtH ratio)*r* = 0.277 *p* = 0.001*r* = 0.16 *p* = 0.051BMI SDS*r* = 0.128 *p* = 0.082*r* = 0.128 *p* = 0.081All variables have been log10 transformed Table 7Multiple linear regression analysis of HDLc as dependent of MRP8/14 and WtH ratioDependentIndependentBRStandardized coefficient 95 % Confidence IntervalLevel of SignificanceHDLcMRP8/14- 0.330- 0.349- 0.169 to - 0.068\<4 × 10^−6^HDLcWaist-to-height ratio- 0.069- 0.160- 0.553 to 0.2200.395B Standardized regression coefficientR multiple correlation coefficientAll variables have been log10 transformed

We found no association between central fatness, measured by WtH ratio, and medication (data not shown).

PA and correlations to cholesterol {#Sec18}
----------------------------------

Neither TC nor LDLc nor HDLc cholesterol fractions correlated with time spent on sedentary PA or with high PA (Table [4](#Tab4){ref-type="table"}).

Discussion {#Sec19}
==========

In our group of patients with JIA most had minimal disease activity, and TC, HDLc and LDLc were found within the normal range. Nevertheless, HDLc showed a negative correlation with MRP8/14, a sensitive marker of inflammation. In contrast, neither TC nor LDLc showed any significant correlation to markers of inflammation.

Our finding of a significant correlation between HDLc and a marker of inflammation is in agreement with two previous findings in JIA \[[@CR14], [@CR15]\]; both found a negative correlation between HDLc and the inflammatory marker CRP. Furthermore a study by Shen et al. \[[@CR33]\] on 58 patients with JIA showed a significant increase in HDLc in parallel with a decrease in CRP in 31 patients with inactive disease after 18 months of anti-inflammatory treatment; the level of LDLc did not change. In contrast, another intervention study of patients with active JIA \[[@CR34]\] showed a more traditional atherogenic lipid profile, with an increased total LDLc and normal HDLc at baseline. After 12 months of anti-inflammatory treatment, the investigators found a large decline in inflammatory markers concomitant with a relatively small decline in LDLc and no change in HDLc.

Most of the patients included in our study had low disease activity according to JADAS27 score, CRP, and ESR. In JIA with low to moderate disease activity, classical biomarkers of inflammation (CRP, ESR) are most often not increased. In order to capture a possible association between cholesterol fractions and low grade inflammation, we also measured MRP8/14. MRP 8 (the same as S100A8) and 14 (S100A9) are calcium-binding, potent pro-inflammatory proteins produced locally by activated phagocytic myeloid cells. MRP8/14 is released as a stable heterodimer into the circulation, where it acts as a pro-inflammatory mediator, promoting activation of inflammatory cells through binding to Toll-like receptors resulting in the production of cytokines such as interleukin-1β and IL-6 that, unimpeded, amplify and perpetuate the inflammation \[[@CR35], [@CR36]\]. The MRP8/14 dimer is measurable in the synovial fluid and the blood, and is correlated with measures of disease activity and risk of relapse after stopping anti-inflammatory medication in JIA \[[@CR37]--[@CR40]\]. While pro-inflammatory cytokines in JIA, such as TNF- α, are easily degraded and found at low concentration in the blood, MRP8/14 is a more abundant and more stable protein also at room temperature. In this study, MRP8/14 correlated significantly with JADAS27 and CRP.

The aforementioned association between inflammation and low levels of HDLc in active RA has been demonstrated in observational studies; no clear causality has been found. However, HDLc particles are important transporters of excess cholesterol from cells, e.g. macrophages in the arterial intima, to the liver ("reverse cholesterol transport") \[[@CR41]\]. Insufficient clearance of cholesterol could partly explain why atherosclerosis is seen in RA patients. Not only the level of HDLc, but also its function may be influenced by inflammation. Upon treatment of patients with RA with an anti-IL-6 R inhibitor, McInnes et al. \[[@CR42]\] found a decrease in the binding of the acute phase reactant, serum amyloid A to HDL particles, as well as an increase in paraoxonase, an antioxidant enzyme connected to HDLc. Thus, HDL particles were reverted from a dysfunctional and pro-inflammatory state to a normal cholesterol-carrying state after anti-inflammatory treatment.

Overweight, defined as BMI SDS above 1, was seen in 30 % of our patients when compared to the Danish gender and age adjusted reference material \[[@CR28]\]; neither BMI nor WtH ratio correlated with cholesterol fractions. However, we found a positive correlation between WtH ratio and MRP8/14. In both genders and regardless of age, WtH ratio is associated not only with BMI but also, independently of BMI, with other risk factors for development of cardiovascular disease, like hypertension and dyslipidemia, \[[@CR43], [@CR44]\]. WtH ratio reflects central, visceral fatness, which is considered the place of origin for development of the low-grade inflammation known to be associated with overweight and obesity. Central fatness may thus influence cardiovascular health in children with JIA by contributing to a continuing low-grade inflammation.

The lipids are measured in a non-fasting state. Older investigations are primarily built on lipids measured in a fasting state, but blood sampling after overnight fasting pose a practical problem in investigations of children living far from laboratories doing the blood sampling. Besides, children are most often in a non-fasting state, and thus the non-fasting levels of lipids may have the highest relevance as risk factors for endothelial damage and cardiovascular disease. In adults, TC and HDLc vary less than 2 % with fasting time; LDHc varies up to 10 % \[[@CR45]\]. The Danish Pediatric reference intervals for lipids are based on blood samples taken from non-fasting children and adolescents.

Although the correlation between HDLc and MRP8/14 was highly significant in our study, the correlation coefficient was only moderate as in the study by Shen et al. \[[@CR33]\], indicating influence by other factors than MRP8/14. In a review on PA and cardiovascular risk factors in children, Andersen et al. \[[@CR46]\] suggested a positive effect of PA on HDLc, with no effect on LDLc and TC. Our study does not support this, as we found no significant correlations between PA and HDLc or LDLc. However, we did not measure fitness. Fitness is built up by regular PA and may thus be a better marker of general health and have a more significant influence on lipids in the blood, than the more sporadic PA that we were able to measure \[[@CR47]\].

The present study has other important limitations. As some of the subgroups had a low number of patients, we have not performed any analysis concerning subgroups of JIA. Considering JIA as a uniform group, especially including sJIA, characterized by high levels of inflammatory mediators, may have inflated the found correlation between MRP8/14 and HDLc. Likewise we cannot exclude that hidden confounders correlated to the pathogenesis of specific subtypes, and not related to disease activity *per se*, may have influenced the findings. We did not find any correlation between treatment regimes and the cholesterol fractions, but we did not look at the specific doses of medicine, which could be of importance, as some medicine may have specific effect on the cholesterol fractions besides the anti-inflammatory effect. Most of our patients received effective anti-inflammatory treatment and had low disease activity. Looking at the level of HDLc before and during anti-inflammatory treatment would be important in future studies.

A cross-sectional descriptive study is at best able to demonstrate associations; causality must be tested in subsequent controlled longitudinal trials. In a setting of updated clinical and biological information, correlations can, nevertheless, have immediate clinical relevance. A strength of our study is that we have looked at a large community-based, representative, and well-described group of patients and have used a sensitive marker of inflammation (MRP8/14).

At present there is evidence that patients with JIA have an increased risk for early development of subclinical atherosclerosis \[[@CR8], [@CR9]\]. No long-term follow-up studies of adults with JIA have yet shown an increased risk of clinically important cardiovascular events in early adult life, underscoring that development of atherosclerosis is a complex process. Availability of effective anti-inflammatory medication and a strategy favoring an early and aggressive use of this may well have a beneficial effect also on vascular health, but adverse lifestyle factors should still be taken into consideration.

Conclusions {#Sec20}
===========

Levels of cholesterol fractions in patients with JIA were found within the normal range. Nonetheless, the level of HDLc was negatively associated to the level of the inflammatory marker MRP8/14, which is in accordance with the concept of inflammation as an important driver for premature development of atherosclerosis in JIA. WtH ratio (a measure of central fatness) was not associated to HDLc, but to MRP8/14, suggestive of central fatness as an additional driving factor for the chronic inflammation in JIA.

Key messages {#Sec21}
============

Even in clinically well-controlled JIA, the level of HDLc is negatively associated to the level of the inflammatory marker MRP8/14.

Central fatness correlates independently to the level of MRP 8/14 and may thus exacerbate the chronic inflammation in JIA.
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